Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
NTRS$171.90+1.55(+0.91%)Northern Trust Celebrates 30 Years in Singapore[10:00:00 PM ET]JELD$1.36-0.05(-3.55%)JELD-WEN Announces Commencement of Exchange Offer and Consent Solicitation for Outstanding 4.875% Senior Notes due 2027 JELD-WEN Holding, Inc. (NYSE: JELD) ("JELD-WEN" or the "Company") today announced that JELD-WEN, Inc. (the "Issuer") commenced an offer to (x) all...[9:51:00 PM ET]CWT$47.15-0.67(-1.40%)California Water Service Group Reports Solid Third Quarter 2026 Results and Successful Execution of Business Strategy[9:15:00 PM ET]EMAT$1.71+0.28(+19.39%)StreetWatch: Evolution Metals Brings Eight-Grade Magnet Portfolio to the U.S. Army's Drone Supply Search[8:30:00 PM ET]BHAVU$10.17-0.04(-0.44%)BHAV Acquisition Corp II Announces Pricing of $100 Million Initial Public Offering[8:30:00 PM ET]MESO$15.03+1.85(+14.04%)Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)[8:19:57 PM ET]ELEK$0.00+0.00(+10.26%)Lithium, Location & Long-Term Vision: Elektros INC. (OTC:ELEK) Eyes an American Supply-Chain Opportunity[8:17:00 PM ET]FFMFF$0.900.00(0.00%)Study confirms FireFly on track to be a significant copper producer[8:03:23 PM ET]RNECF$19.41+2.07(+11.94%)Renesas Reports Financial Results for the Third Quarter Ended September 30, 2026[8:00:00 PM ET]RNECF$19.41+2.07(+11.94%)Renesas Announces Consolidated Forecasts[8:00:00 PM ET]ELEK$0.00+0.00(+10.26%)The Next Chapter in American Lithium: Elektros (OTC:ELEK) Spotlights a Potential New York Opportunity[8:00:00 PM ET]

REPL · NASDAQ

Replimune Group, Inc.

$15.82 +0.57 (+4.57%)

Company overview

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors and in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein designed to block the inhibition of the immune response caused by CTLA-4, and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.5B
Employees
479
Headquarters
Woburn, MA
Website
replimune.com
CEO
Sushil Patel
Listed
July 20, 2018
P/E
-4.42
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$848,000
Operating income
-$326M
EBITDA
-$311M
Net income
-$315M
EPS
-$3.58
Total assets
$334M
Total debt
$76.3M
Earnings yield
-22.63%

Price chart

1.765.659.5413.4317.33
REPL 1D NASDAQ O12.96H16.75L12.54C16.07+3.02 (+23.14%)Vol2.34M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
REPLReplimune Group, Inc. Stock news Replimune: 3 Key Takeaways for Long-Term Investors The Motley Fool
REPLReplimune Group, Inc. Stock news Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript Seeking Alpha
REPLReplimune Group, Inc. Press release Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update GlobeNewswire
REPLReplimune Group, Inc. Press release Lifshitz Law PLLC Announces Investigations of Replimune Group, Inc. (NASDAQ: REPL), Datavault AI Inc. (NASDAQ: DVLT), Blaize Holdings, Inc. (NASDAQ: BZAI), and ARS Pharmaceuticals (NASDAQ: SPRY) ACCESS Newswire
REPLReplimune Group, Inc. Press release Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026 GlobeNewswire
REPLReplimune Group, Inc. Legal REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & GlobeNewswire
REPLReplimune Group, Inc. Press release Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma GlobeNewswire
REPLReplimune Group, Inc. Legal REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky PR Newswire
REPLReplimune Group, Inc. Legal REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th GlobeNewsWire
REPLReplimune Group, Inc. Press release DEADLINE ALERT for REPL, DVLT, and UWMC: The Law Offices of GlobeNewswire
REPLReplimune Group, Inc. Legal REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact SueWallSt GlobeNewswire
REPLReplimune Group, Inc. Legal Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1 Newsfile Corp
REPLReplimune Group, Inc. Legal REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact Levi & Korsinsky GlobeNewsWire
REPLReplimune Group, Inc. Legal REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 PRNewsWire
REPLReplimune Group, Inc. Legal REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm PR Newswire
REPLReplimune Group, Inc. Legal Portnoy Law Firm Announces Class Action on Behalf of GlobeNewswire
REPLReplimune Group, Inc. Legal REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt GlobeNewswire
REPLReplimune Group, Inc. Legal REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses GuruFocus
REPLReplimune Group, Inc. Legal REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses PRNewsWire
REPLReplimune Group, Inc. Legal REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt PR Newswire
See more
FAQ

Questions about Replimune Group, Inc.

What does Replimune Group, Inc. do?
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors and in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein designed to block the inhibition of the immune response caused by CTLA-4, and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
What is REPL's market cap?
Replimune Group, Inc. (REPL) is a listed stock with a live quote. The latest market cap on this page is $1.5B.
Where is Replimune Group, Inc. headquartered?
Replimune Group, Inc. is headquartered in Woburn, MA.
How do I get REPL news from the API?
Call GET /v1/news?tickers=REPL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does REPL news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for REPL, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the REPL price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs